Top

Published in:

Open Access 01-12-2020 | Letter

Letter to the editor: Response to Giardiello D, Antoniou AC, Mariani L, Easton DF, Steyerberg EW

Authors: Chang Ming, Valeria Viassolo, Nicole Probst-Hensch, Pierre O. Chappuis, Ivo D. Dinov, Maria C. Katapodi

Published in: Breast Cancer Research | Issue 1/2020

Excerpt

We appreciate the opportunity to submit a response to the Letter to the Editor by Giardiello and colleagues [1] addressing our publication in Breast Cancer Research [2]. …

Giardiello D, Antoniou AC, Mariani L, Easton DF, Steyerberg EW. Letter to the editor: a response to Ming’s study on machine learning techniques for personalized breast cancer risk prediction. Breast Cancer Res. 2020;22(1):17.CrossRef

Ming C, Viassolo V, Probst-Hensch N, Chappuis PO, Dinov ID, Katapodi MC. Machine learning techniques for personalized breast cancer risk prediction: comparison with the BCRAT and BOADICEA models. Breast Cancer Res. 2019;21(1):75.CrossRef

Wang X, Huang Y, Li L, Dai H, Song F, Chen K. Assessment of performance of the Gail model for predicting breast cancer risk: a systematic review and meta-analysis with trial sequential analysis. Breast Cancer Res. 2018;20(1):18.CrossRef

Steyerberg EW, Harrell FE, Borsboom GJJM, Eijkemans MJC, Vergouwe Y, Habbema JDF. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001;54(8):774–81.CrossRef

Luo W, Phung D, Tran T, Gupta S, Rana S, Karmakar C, et al. Guidelines for developing and reporting machine learning predictive models in biomedical research: a multidisciplinary view. J Med Internet Res. 2016;18(12):e323.CrossRef

Niculescu-Mizil A, Caruana R. Predicting good probabilities with supervised learning. Proceedings of the 22nd international conference on Machine learning. Bonn: Association for Computing Machinery; 2005. p. 625–32.

Brinton JT, Hendrick RE, Ringham BM, Kriege M, Glueck DH. Improving the diagnostic accuracy of a stratified screening strategy by identifying the optimal risk cutoff. Cancer Causes Control. 2019;30(10):1145–55.CrossRef

Title: Letter to the editor: Response to Giardiello D, Antoniou AC, Mariani L, Easton DF, Steyerberg EW
Authors: Chang Ming
Valeria Viassolo
Nicole Probst-Hensch
Pierre O. Chappuis
Ivo D. Dinov
Maria C. Katapodi
Publication date: 01-12-2020
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 1/2020
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/s13058-020-01274-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2020

Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer

Correction to: Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study

Immune phenotype of patients with stage IV metastatic inflammatory breast cancer

Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis

Modeling the natural history of ductal carcinoma in situ based on population data

CRIPTO antagonist ALK4L75A-Fc inhibits breast cancer cell plasticity and adaptation to stress

Keynote webinar | Spotlight on antibody–drug conjugates in cancer